Thermo Fisher Scientific Inc. (NYSE:TMO) Shares Acquired by Commerce Bank

Commerce Bank raised its position in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 0.7% during the 3rd quarter, according to its most recent disclosure with the SEC. The fund owned 229,601 shares of the medical research company's stock after purchasing an additional 1,534 shares during the period. Thermo Fisher Scientific comprises approximately 0.9% of Commerce Bank's portfolio, making the stock its 23rd biggest holding. Commerce Bank owned 0.06% of Thermo Fisher Scientific worth $142,024,000 at the end of the most recent quarter.

A number of other large investors have also made changes to their positions in TMO. BDF Gestion acquired a new position in shares of Thermo Fisher Scientific in the 2nd quarter worth $6,368,000. Nisa Investment Advisors LLC lifted its stake in shares of Thermo Fisher Scientific by 6.2% in the 3rd quarter. Nisa Investment Advisors LLC now owns 140,708 shares of the medical research company's stock valued at $87,093,000 after purchasing an additional 8,180 shares during the period. Simplify Asset Management Inc. raised its stake in Thermo Fisher Scientific by 67.4% during the 3rd quarter. Simplify Asset Management Inc. now owns 13,770 shares of the medical research company's stock worth $8,518,000 after buying an additional 5,546 shares during the period. Simmons Bank lifted its position in Thermo Fisher Scientific by 60.2% during the third quarter. Simmons Bank now owns 8,224 shares of the medical research company's stock worth $5,087,000 after acquiring an additional 3,090 shares during the last quarter. Finally, ORG Partners LLC raised its position in shares of Thermo Fisher Scientific by 216.6% in the second quarter. ORG Partners LLC now owns 1,640 shares of the medical research company's stock valued at $890,000 after buying an additional 1,122 shares in the last quarter. Institutional investors and hedge funds own 89.23% of the company's stock.

Thermo Fisher Scientific Stock Up 0.3 %

Shares of NYSE TMO traded up $1.71 during midday trading on Wednesday, hitting $510.83. 978,287 shares of the company's stock were exchanged, compared to its average volume of 1,489,230. The firm's fifty day simple moving average is $581.75 and its 200-day simple moving average is $581.46. Thermo Fisher Scientific Inc. has a twelve month low of $476.45 and a twelve month high of $627.88. The company has a market cap of $195.39 billion, a PE ratio of 31.92, a P/E/G ratio of 3.39 and a beta of 0.79. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.63 and a quick ratio of 1.26.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last released its quarterly earnings results on Wednesday, October 23rd. The medical research company reported $5.28 EPS for the quarter, topping the consensus estimate of $5.25 by $0.03. Thermo Fisher Scientific had a return on equity of 17.49% and a net margin of 14.48%. The business had revenue of $10.60 billion for the quarter, compared to analysts' expectations of $10.63 billion. During the same quarter in the previous year, the firm posted $5.69 earnings per share. The company's revenue was up .2% compared to the same quarter last year. Research analysts predict that Thermo Fisher Scientific Inc. will post 21.67 EPS for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Wednesday, January 15th. Investors of record on Friday, December 13th will be given a dividend of $0.39 per share. This represents a $1.56 dividend on an annualized basis and a yield of 0.31%. The ex-dividend date of this dividend is Friday, December 13th. Thermo Fisher Scientific's dividend payout ratio (DPR) is presently 9.78%.

Thermo Fisher Scientific declared that its Board of Directors has initiated a share repurchase plan on Friday, November 15th that allows the company to buyback $4.00 billion in outstanding shares. This buyback authorization allows the medical research company to buy up to 2% of its stock through open market purchases. Stock buyback plans are often a sign that the company's board of directors believes its stock is undervalued.

Analyst Upgrades and Downgrades

Several equities analysts recently commented on the stock. Bank of America boosted their price objective on shares of Thermo Fisher Scientific from $600.00 to $675.00 and gave the company a "buy" rating in a research note on Monday, September 16th. Royal Bank of Canada decreased their target price on Thermo Fisher Scientific from $767.00 to $718.00 and set an "outperform" rating for the company in a report on Thursday, October 24th. Sanford C. Bernstein lowered their target price on Thermo Fisher Scientific from $625.00 to $620.00 and set a "market perform" rating on the stock in a report on Thursday, October 24th. Robert W. Baird cut their price target on Thermo Fisher Scientific from $632.00 to $622.00 and set an "outperform" rating for the company in a report on Thursday, October 24th. Finally, Stifel Nicolaus dropped their price objective on Thermo Fisher Scientific from $680.00 to $665.00 and set a "buy" rating for the company in a report on Thursday, October 24th. Four analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average price target of $649.33.

Insiders Place Their Bets

In related news, EVP Gianluca Pettiti sold 300 shares of the business's stock in a transaction dated Friday, October 25th. The shares were sold at an average price of $560.16, for a total transaction of $168,048.00. Following the transaction, the executive vice president now directly owns 16,663 shares in the company, valued at approximately $9,333,946.08. The trade was a 1.77 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, SVP Michael A. Boxer sold 2,000 shares of the stock in a transaction on Friday, October 25th. The stock was sold at an average price of $560.16, for a total transaction of $1,120,320.00. Following the completion of the transaction, the senior vice president now directly owns 12,736 shares in the company, valued at $7,134,197.76. The trade was a 13.57 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 37,150 shares of company stock worth $20,651,865 over the last quarter. Company insiders own 0.34% of the company's stock.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.